Market Overview
The ACE inhibitors drug market is predicted
to develop at a compound annual growth rate (CAGR) of 5.92% from 2024 to 2033,
when it is projected to reach USD 14.32 billion, based on an average growth pattern.
The market is estimated to reach a value of USD 8.5 billion in 2024.
SOURCE: We Market Research
Angiotensin-converting
enzyme (ACE) inhibitors are a class of medications commonly used to treat
conditions such as hypertension, heart failure, and chronic kidney disease.
They work by blocking the activity of the angiotensin-converting enzyme, a key
player in the renin-angiotensin-aldosterone system. This system regulates blood
pressure and fluid balance. By inhibiting ACE, these drugs reduce the
production of angiotensin II, a potent vasoconstrictor, and decrease the
secretion of aldosterone, leading to vasodilation and decreased fluid
retention. As a result, ACE inhibitors help relax blood vessels, lower blood
pressure, and improve cardiac function, making them valuable in managing
cardiovascular and renal disorders.
The ACE
inhibitors drug market is driven by several key factors. Firstly, the rising
prevalence of cardiovascular diseases, hypertension, and chronic kidney
disorders globally has increased the demand for effective pharmaceutical
interventions. Additionally, the aging population contributes to a growing
patient pool requiring cardiovascular care. The emphasis on preventive
healthcare and awareness campaigns further fuels market growth. Advances in
research and development, leading to the introduction of novel ACE inhibitors
with enhanced efficacy and fewer side effects, also contribute to market
expansion. Furthermore, the increasing healthcare expenditure and accessibility
to medical services in developing regions amplify the market's potential,
fostering continued innovation and market competitiveness.
Market Scope
Report Attributes |
Description |
Market Size in 2024 |
USD 8.5 Billion |
Market Forecast in 2033 |
USD 14.32 Billion |
CAGR % 2024-2033 |
5.92% |
Base Year |
2023 |
Historic Data |
2016-2022 |
Forecast Period |
2024-2033 |
Report USP
|
Production, Consumption, company share, company
heatmap, company production capacity, growth factors and more |
Segments Covered |
By Product Type, By Drug, By Application, By Dosage Form, By Distribution
Channel and By Region |
Regional Scope |
North America, Europe, APAC, South America and
Middle East and Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic
Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia;
Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa;
Nigeria |
ACE inhibitors drug Industry: Dynamics & Restrains
Market Drivers
Clinical
Effectiveness and Established Track Record - The
clinical effectiveness and established track record of ACE inhibitors drive
their prominence in the pharmaceutical market. With a well-documented history
of efficacy and safety in managing hypertension and heart-related conditions,
healthcare professionals often rely on these drugs as first-line treatments.
Patients benefit from their proven ability to reduce blood pressure, mitigate
cardiovascular risks, and improve outcomes. The familiarity and positive
clinical experiences contribute to a high level of confidence among prescribers
and patients, establishing ACE inhibitors as a trusted and widely prescribed
class of medications for cardiovascular health.
Prevalence of
Hypertension and Cardiovascular Diseases- The
prevalence of hypertension and cardiovascular diseases significantly propels
the ACE inhibitors drug market. As these health conditions continue to affect a
substantial global population, there is a growing demand for effective
antihypertensive medications. ACE inhibitors, renowned for their efficacy in
managing hypertension and related cardiovascular issues, become pivotal in
addressing this widespread health concern. The escalating number of individuals
diagnosed with hypertension creates a sustained market need for medications
that can effectively regulate blood pressure and improve cardiovascular
outcomes. This high prevalence underscores the pivotal role ACE inhibitors play
in meeting the therapeutic requirements of a large and expanding patient
demographic.
Market restrains
Competition from
Alternative Therapies- Competition from
alternative therapies poses a constraint on the ACE inhibitors drug market. The
availability of various antihypertensive medications, such as angiotensin II
receptor blockers (ARBs), calcium channel blockers, and diuretics, presents
physicians with diverse treatment options. Patient-specific factors and
preferences, as well as considerations related to efficacy and side effects,
contribute to the choice of alternative therapies over ACE inhibitors. The
competitive landscape challenges the market share of ACE inhibitors, requiring
pharmaceutical manufacturers to navigate a dynamic environment and address
evolving preferences among healthcare providers and patients seeking tailored
solutions for hypertension management.
We Market Research:
ACE inhibitors drug Dashboard
Our marketing platform has an extensive dashboard that gives customers insightful information about market changes over time. A screenshot of our dashboard is provided below, and unique PDF login credentials will be sent to enable access to this informative resource.
ACE inhibitors drug Segmentation
Market- By Product Type Analysis
By Product Type, the ACE inhibitors drug Market is Categories into Phosphonate-Containing Agents, Dicarboxylate-Containing Agents, Sulfhydryl-Containing Agents. The Dicarboxylate-Containing Agents segment accounts for the largest share of around 41% in 2022.
Compared to other categories, DCAs like as
lisinopril, ramipril, and enalapril have less side effects but still have a
strong blood pressure-lowering impact. They are highly favored by both patients
and physicians because of this ideal balance between comfort and effectiveness.
The
following segments are part of an in-depth analysis of the global ACE
inhibitors drug market:
Market Segments |
|
By Drug |
·
Lisinopril ·
Ramipril ·
Enalapril ·
Benazepril ·
Fosinopril ·
Captopril ·
Moexipril ·
Others |
By Application |
·
Heart Failure ·
Hypertension ·
Diabetes ·
Heart Attack ·
Chronic Kidney Disease ·
Others |
By Dosage Form |
·
Oral Tablets ·
Oral Solution |
By Distribution Channel |
·
Retail Pharmacy ·
Hospital Pharmacy ·
E-Commerce Websites ·
Online Drug Stores |
ACE inhibitors drug Industry: Regional Analysis
North America Market Forecast
North America dominate the ACE inhibitors drug Market with the highest revenue generating market with share of more than 48%. One of the many factors propelling the ACE inhibitor market in North America is the rising incidence of cardiovascular diseases in the region. The favorable reimbursement regulations and the well-established healthcare system both contribute to the widespread use of ACE inhibitors. Big pharmaceutical companies in North America engage in active research and development, leading to the introduction of new drugs and maintaining the market's growth momentum.
Europe Market Statistics
Europe is the
second-largest market for ACE inhibitors drug. The aging population in Europe
is driving the demand for ACE inhibitors since they are more at risk for
cardiovascular problems. The strict regulatory environment in the area
facilitates the creation, licensing, and marketing of drugs. Because of this,
ACE inhibitors—which are crucial for treating ailments including heart failure
and hypertension—find a strong market in Europe. The need for these drugs is
fueled in part by the focus on patient outcomes and healthcare quality.
Asia Pacific Market Forecasts
Asia Pacific is expected
to be the fastest-growing market for ACE inhibitors drug during the forecast
period. The market for ACE inhibitors is growing in the Asia-Pacific area for a
number of reasons. The need for these medications is fueled by a growing
prevalence of hypertension and related disorders as well as a growing awareness
of cardiovascular diseases. Because of the region's expanding healthcare
spending and developing healthcare infrastructure, which enhance accessibility,
ACE inhibitors are a vital part of cardiovascular therapy. The changing
lifestyle and changing demographics are contributing factors to the increase in
cardiovascular disease cases.
Key Market Players
The ACE
inhibitors drug Market is dominated by a few large companies, such as
·
GlaxoSmithKline
·
Teva Pharmaceutical Industries
Ltd.
·
Lupin Limited
·
Cipla
·
Torrent Pharmaceuticals Ltd.
·
Sun Pharmaceutical Industries
Ltd.
·
Macleods Pharmaceuticals
Limited
·
Zydus Cadila
·
Mylan
·
Sandoz
·
Accord Healthcare
·
Dr. Reddy's Laboratories Ltd.
·
Cadila Healthcare Limited
·
Novartis AG
·
Pfizer Inc.
·
Merck & Co.
·
AstraZeneca
·
Sanofi
·
Boehringer Ingelheim
·
Others
Recent Developments:
·
May 2021, Novartis declared
that the FDA had approved Entresto, a novel ACE inhibitor medication, for the
management of heart failure. It has been demonstrated that this medication
lowers the risk of hospitalization and death in heart failure patients.
·
November 2020, The COVID-19
vaccine's 95% efficacy was revealed by Pfizer and BioNTech in their joint
clinical study results. The creation of the COVID-19 vaccine has been a
significant milestone for Pfizer, a prominent manufacturer of ACE inhibitors.
1.
Global
ACE inhibitors drug Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global ACE inhibitors drug
Market Scope and Market Estimation
1.2.1. Global ACE inhibitors drug Overall
Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)
1.2.2. Global ACE inhibitors drug
Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033
1.3. Market Segmentation
1.3.1. Component of Global ACE
inhibitors drug Market
1.3.2. Technology of Global ACE
inhibitors drug Market
1.3.3. Application of Global ACE
inhibitors drug Market
1.3.4. Region of Global ACE inhibitors
drug Market
2.
Executive Summary
2.1. Global ACE inhibitors drug Market Industry Trends under COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global ACE inhibitors drug Market
Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and
Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global ACE inhibitors drug
Market Estimates & Historical Trend
Analysis (2019 - 2022)
4.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by PRODUCT TYPE
4.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by PRODUCT TYPE, 2019 to 2033
4.1.1. Phosphonate-Containing Agents
4.1.2. Dicarboxylate-Containing Agents
4.1.3. Sulfhydryl-Containing Agents
5.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by Drug
5.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by Drug, 2019 to 2033
5.1.1. Lisinopril
5.1.2. Ramipril
5.1.3. Enalapril
5.1.4. Benazepril
5.1.5. Fosinopril
5.1.6. Captopril
5.1.7. Moexipril
5.1.8. Others
6.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by Application
6.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by Application,
2019 to 2033
6.1.1. Heart Failure
6.1.2. Hypertension
6.1.3. Diabetes
6.1.4. Heart Attack
6.1.5. Chronic Kidney Disease
6.1.6. Others
7.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by DOSAGE FORM
7.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by Application,
2019 to 2033
7.1.1. Oral Tablets
7.1.2. Oral Solution
8.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by DISTRIBUTION
CHANNEL
8.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by Application,
2019 to 2033
8.1.1. Retail Pharmacy
8.1.2. Hospital Pharmacy
8.1.3. E-Commerce Websites
8.1.4. Online Drug Stores
9.
Global ACE inhibitors drug
Market Estimates & Forecast Trend
Analysis, by Region
9.1. Global ACE inhibitors drug
Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Middle East & Africa
9.1.5. South America
10. North America ACE
inhibitors drug Market: Estimates &
Forecast Trend Analysis
10.1.
North
America ACE inhibitors drug Market Assessments & Key Findings
10.1.1. North America ACE inhibitors
drug Market Introduction
10.1.2. North America ACE inhibitors
drug Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
10.1.2.1. By PRODUCT TYPE
10.1.2.2. By Drug
10.1.2.3. By Application
10.1.2.4. By DOSAGE FORM
10.1.2.5. By DISTRIBUTION
CHANNEL
10.1.2.6. By Country
10.1.2.6.1. The U.S.
10.1.2.6.2. Canada
10.1.2.6.3. Mexico
11. Europe ACE
inhibitors drug Market: Estimates &
Forecast Trend Analysis
11.1. Europe ACE inhibitors drug
Market Assessments & Key Findings
11.1.1. Europe ACE inhibitors drug
Market Introduction
11.1.2. Europe ACE inhibitors drug
Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
11.1.2.1. By PRODUCT TYPE
11.1.2.2. By Drug
11.1.2.3. By Application
11.1.2.4. By DOSAGE FORM
11.1.2.5. By DISTRIBUTION
CHANNEL
11.1.2.6. By Country
11.1.2.6.1. Germany
11.1.2.6.2. U.K.
11.1.2.6.3. France
11.1.2.6.4. Italy
11.1.2.6.5. Spain
11.1.2.6.6. Russia
11.1.2.6.7. Rest of Europe
12. Asia Pacific ACE
inhibitors drug Market: Estimates &
Forecast Trend Analysis
12.1. Asia Pacific Market Assessments
& Key Findings
12.1.1. Asia Pacific ACE inhibitors drug
Market Introduction
12.1.2. Asia Pacific ACE inhibitors drug
Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
12.1.2.1. By PRODUCT TYPE
12.1.2.2. By Drug
12.1.2.3. By Application
12.1.2.4. By DOSAGE FORM
12.1.2.5. By DISTRIBUTION
CHANNEL
12.1.2.6. By Country
12.1.2.6.1. China
12.1.2.6.2. Japan
12.1.2.6.3. India
12.1.2.6.4. Australia
12.1.2.6.5. South Korea
12.1.2.6.6. ASEAN
12.1.2.6.7. Rest of Asia Pacific
13. Middle East & Africa ACE
inhibitors drug Market: Estimates &
Forecast Trend Analysis
13.1. Middle East & Africa Market
Assessments & Key Findings
13.1.1. Middle
East & Africa ACE
inhibitors drug Market Introduction
13.1.2. Middle
East & Africa ACE
inhibitors drug Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
13.1.2.1. By PRODUCT TYPE
13.1.2.2. By Drug
13.1.2.3. By Application
13.1.2.4. By DOSAGE FORM
13.1.2.5. By DISTRIBUTION
CHANNEL
13.1.2.6. By Country
13.1.2.6.1. U.A.E.
13.1.2.6.2. Saudi Arabia
13.1.2.6.3. Egypt
13.1.2.6.4. South Africa
13.1.2.6.5. Rest of Middle East & Africa
14. South America
ACE inhibitors drug Market: Estimates
& Forecast Trend Analysis
14.1. South America Market Assessments
& Key Findings
14.1.1. South America ACE inhibitors
drug Market Introduction
14.1.2. South America ACE inhibitors
drug Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
14.1.2.1. By PRODUCT TYPE
14.1.2.2. By Drug
14.1.2.3. By Application
14.1.2.4. By DOSAGE FORM
14.1.2.5. By DISTRIBUTION
CHANNEL
14.1.2.6. By Country
14.1.2.6.1. Brazil
14.1.2.6.2. Argentina
14.1.2.6.3. Colombia
14.1.2.6.4. Rest of South America
15. Competition Landscape
15.1. Global ACE inhibitors drug
Market Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
15.2. Global ACE inhibitors drug
Market Competition White Space Analysis, By Application
15.3. Global ACE inhibitors drug
Market Competition Heat Map Analysis, By Application
15.4. Global ACE inhibitors drug
Market Concentration & Company Market Shares (%) Analysis, 2022
16. Company Profiles
16.1.
GlaxoSmithKline
16.1.1. Company Overview & Key Stats
16.1.2. Financial Performance & KPIs
16.1.3. Product Portfolio
16.1.4. Business Strategy & Recent
Developments
* Similar details would be provided
for all the players mentioned below
16.2. Teva
Pharmaceutical Industries Ltd.
16.3. Lupin Limited
16.4. Cipla
16.5. Torrent
Pharmaceuticals Ltd.
16.6. Sun
Pharmaceutical Industries Ltd.
16.7. Macleods
Pharmaceuticals Limited
16.8. Zydus Cadila
16.9. Mylan
16.10. Sandoz
16.11. Accord
Healthcare
16.12. Dr. Reddy's
Laboratories Ltd.
16.13. Cadila
Healthcare Limited
16.14. Novartis AG
16.15. Pfizer Inc.
16.16. Merck &
Co.
16.17. AstraZeneca
16.18. Sanofi
16.19. Boehringer
Ingelheim
16.20. Others
16.21. Others
17. Research
Methodology
17.1. External Transportations /
Databases
17.2. Internal Proprietary Database
17.3. Primary Research
17.4. Secondary Research
17.5. Assumptions
17.6. Limitations
17.7. Report FAQs
18. Research
Findings & Conclusion
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
ACE inhibitors drug Market was valued at USD 8.5 Billion in 2024.
ACE inhibitors drug Market size will increase at approximate CAGR of 5.92% during the forecasted period.
Major companies operating within the ACE inhibitors drug Market are GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Lupin Limited, Cipla, Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Macleods Pharmaceuticals Limited, Zydus Cadila, Mylan, Sandoz, Accord Healthcare, Dr. Reddy's Laboratories Ltd., Cadila Healthcare Limited, Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim and Other.
North America dominates the market with an active share of 48%.
Only Three Thousand Four Hundred Ninety Nine US dollar
Only Four Thousand Four Hundred Ninety Nine US dollar
Only Five Thousand Four Hundred Ninety Nine US dollar